---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-202349"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:17:11.790193+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q2 2023 net loss $9.4M; SNS-101 Phase 1/2 enrolling 6 patients

## Summary
- Cash, cash equivalents and marketable securities $78.8M at June 30, 2023, down from $107.1M at Dec 31, 2022; cash runway into H2 2025.
- Net loss $9.4M vs $10.5M YoY; R&D expenses $4.8M (down from $6.4M) due to restructuring and lower manufacturing costs.
- G&A expenses $5.4M included $1.56M non-recurring stockholder activism costs related to the 2023 annual meeting.
- SNS-101 Phase 1/2 enrolled 6 patients across 3 cohorts; combination arm with Libtayo (cemiplimab) expected Q4 2023; PK/safety data by year-end 2023.
- Robert Schreiber appointed Chair of Immuno-Oncology Advisory Board; SNS-102 and SNS-103 lead optimization completed, candidate selection expected in 2023.

## SEC filing metadata
- accession: 0001193125-23-202349
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/0001193125-23-202349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/d518119d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-202349
- JSON: https://secwatch.observer/filing/0001193125-23-202349.json
- Plain text: https://secwatch.observer/filing/0001193125-23-202349.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $9.4 million.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss was $9.4 million
  - Result: reported results
  source text: Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312523202349/0001193125-23-202349-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.